NYSE:EBS Emergent BioSolutions (EBS) Stock Forecast, Price & News $8.25 +0.05 (+0.61%) (As of 11:57 AM ET) Add Compare Share Share Today's Range$8.16▼$8.4550-Day Range$8.10▼$13.2152-Week Range$7.74▼$36.14Volume347,227 shsAverage Volume1.49 million shsMarket Capitalization$416.20 millionP/E RatioN/ADividend YieldN/APrice Target$28.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Emergent BioSolutions MarketRank™ ForecastAnalyst RatingHold2.20 Rating ScoreUpside/Downside242.3% Upside$28.00 Price TargetShort InterestHealthy14.37% of Float Sold ShortDividend StrengthN/ASustainability-1.40Upright™ Environmental ScoreNews Sentiment0.11Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.41) to $0.72 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.34 out of 5 starsMedical Sector507th out of 1,980 stocksPharmaceutical Preparations Industry225th out of 978 stocks 3.1 Analyst's Opinion Consensus RatingEmergent BioSolutions has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.00, Emergent BioSolutions has a forecasted upside of 242.3% from its current price of $8.18.Amount of Analyst CoverageEmergent BioSolutions has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted14.37% of the float of Emergent BioSolutions has been sold short.Short Interest Ratio / Days to CoverEmergent BioSolutions has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Emergent BioSolutions has recently decreased by 4.51%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEmergent BioSolutions does not currently pay a dividend.Dividend GrowthEmergent BioSolutions does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEmergent BioSolutions has received a 73.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Influenza vaccines", "Cholera vaccines", and "Antibiotics" products. See details.Environmental SustainabilityThe Environmental Impact score for Emergent BioSolutions is -1.40. Previous Next 2.3 News and Social Media Coverage News SentimentEmergent BioSolutions has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Emergent BioSolutions this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -87% compared to the previous 30 days.MarketBeat Follows6 people have added Emergent BioSolutions to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Emergent BioSolutions insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.90% of the stock of Emergent BioSolutions is held by insiders.Percentage Held by Institutions80.44% of the stock of Emergent BioSolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Emergent BioSolutions are expected to grow in the coming year, from ($1.41) to $0.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent BioSolutions is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent BioSolutions is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEmergent BioSolutions has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Emergent BioSolutions (NYSE:EBS) StockEmergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.Read More Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter. Email Address EBS Stock News HeadlinesMay 31, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Galapagos (GLPG) and Emergent Biosolutions (EBS)May 31, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Emergent BioSolutionsJune 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 26, 2023 | americanbankingnews.comEmergent BioSolutions Inc. (NYSE:EBS) to Post Q3 2024 Earnings of $0.90 Per Share, Zacks Research ForecastsMay 25, 2023 | americanbankingnews.comEmergent BioSolutions Inc. (NYSE:EBS) Given Average Rating of "Hold" by BrokeragesMay 19, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Emergent Biosolutions (EBS) and HeartBeam (BEAT)May 19, 2023 | msn.comBenchmark Reiterates Emergent Biosolutions (EBS) Buy RecommendationMay 18, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Emergent BioSolutions (NYSE:EBS)June 2, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. May 17, 2023 | americanbankingnews.comEmergent BioSolutions Inc. (NYSE:EBS) Sees Significant Drop in Short InterestMay 16, 2023 | marketwatch.com8-K: Emergent BioSolutions Inc.May 15, 2023 | finance.yahoo.comWhy Emergent BioSolutions Stock Inched Slightly Higher TodayMay 15, 2023 | finance.yahoo.comBavarian Nordic Completes Acquisition of Travel Vaccine Portfolio from Emergent BioSolutionsMay 15, 2023 | finance.yahoo.comEmergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian NordicMay 12, 2023 | americanbankingnews.comEmergent BioSolutions (NYSE:EBS) Shares Gap Down on Disappointing EarningsMay 11, 2023 | finance.yahoo.comEmergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDTMay 10, 2023 | bizjournals.comEmergent BioSolutions’ share price sinks following Q1 earnings. But it’s betting big on Narcan.May 10, 2023 | finance.yahoo.comEmergent (EBS) Q1 Earnings Miss Estimates, Revenues BeatMay 10, 2023 | finance.yahoo.comEmergent BioSolutions (EBS) Q1 2023 Earnings Call TranscriptMay 9, 2023 | msn.comRecap: Emergent BioSolutions Q1 EarningsMay 9, 2023 | finance.yahoo.comEmergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue EstimatesMay 9, 2023 | finance.yahoo.comEmergent BioSolutions Reports Financial Results For First Quarter 2023May 8, 2023 | americanbankingnews.comEmergent BioSolutions (EBS) Scheduled to Post Earnings on TuesdayApril 25, 2023 | americanbankingnews.comEmergent BioSolutions Inc. (NYSE:EBS) Given Average Recommendation of "Hold" by BrokeragesApril 24, 2023 | bizjournals.comOpioid overdose antidote Narcan will soon be available over the counter. Here’s what D.C.-area employers can be doing.April 21, 2023 | msn.comEmergent Plans $50 Price Point For Narcan OTC Version For Opioid Overdose ReversalApril 20, 2023 | finance.yahoo.comEmergent aims to price over-the-counter Narcan at about $50See More Headlines EBS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EBS Company Calendar Last Earnings5/09/2023Today6/02/2023Next Earnings (Estimated)8/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNYSE:EBS CUSIP29089Q10 CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees2,500Year FoundedN/APrice Target and Rating Average Stock Price Forecast$28.00 High Stock Price Forecast$55.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+242.3%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($8.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-223,800,000.00 Net Margins-41.20% Pretax Margin-38.73% Return on Equity-20.18% Return on Assets-9.52% Debt Debt-to-Equity Ratio0.37 Current Ratio1.00 Quick Ratio0.70 Sales & Book Value Annual Sales$1.12 billion Price / Sales0.37 Cash Flow$0.71 per share Price / Cash Flow11.55 Book Value$23.84 per share Price / Book0.34Miscellaneous Outstanding Shares50,450,000Free Float49,489,000Market Cap$412.68 million OptionableOptionable Beta0.93 Key ExecutivesRobert G. KramerPresident, Chief Executive Officer & DirectorAdam Robert HaveyChief Operating Officer & EVP-Business OperationsRichard Scott LindahlChief Financial Officer, Treasurer & Executive VPSharon M. SolomonChief Information Officer & Senior Vice PresidentKelly WarfieldSenior Vice President-Science & DevelopmentKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTVanda PharmaceuticalsNASDAQ:VNDALexicon PharmaceuticalsNASDAQ:LXRXRigel PharmaceuticalsNASDAQ:RIGLSpectrum PharmaceuticalsNASDAQ:SPPIView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Sold 120,270 shares on 5/22/2023Ownership: 0.732%New York State Common Retirement FundSold 30,465 shares on 5/18/2023Ownership: 0.362%JPMorgan Chase & Co.Sold 174,182 shares on 5/18/2023Ownership: 0.139%Thrivent Financial for LutheransSold 1,543 shares on 5/17/2023Ownership: 0.087%Susquehanna International Group LLPBought 1,100 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EBS Stock - Frequently Asked Questions Should I buy or sell Emergent BioSolutions stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares. View EBS analyst ratings or view top-rated stocks. What is Emergent BioSolutions' stock price forecast for 2023? 5 brokerages have issued 12 month price targets for Emergent BioSolutions' stock. Their EBS share price forecasts range from $9.00 to $55.00. On average, they predict the company's stock price to reach $28.00 in the next year. This suggests a possible upside of 242.3% from the stock's current price. View analysts price targets for EBS or view top-rated stocks among Wall Street analysts. How have EBS shares performed in 2023? Emergent BioSolutions' stock was trading at $11.81 at the start of the year. Since then, EBS shares have decreased by 30.7% and is now trading at $8.18. View the best growth stocks for 2023 here. Are investors shorting Emergent BioSolutions? Emergent BioSolutions saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 6,650,000 shares, a decrease of 7.5% from the April 15th total of 7,190,000 shares. Based on an average trading volume of 1,810,000 shares, the days-to-cover ratio is presently 3.7 days. Currently, 15.1% of the company's shares are sold short. View Emergent BioSolutions' Short Interest. When is Emergent BioSolutions' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023. View our EBS earnings forecast. How were Emergent BioSolutions' earnings last quarter? Emergent BioSolutions Inc. (NYSE:EBS) released its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($3.17) earnings per share for the quarter, missing analysts' consensus estimates of ($1.67) by $1.50. The biopharmaceutical company earned $165.10 million during the quarter, compared to analysts' expectations of $142.85 million. Emergent BioSolutions had a negative net margin of 41.20% and a negative trailing twelve-month return on equity of 20.18%. The firm's revenue was down 46.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.18 EPS. What ETFs hold Emergent BioSolutions' stock? ETFs with the largest weight of Emergent BioSolutions (NYSE:EBS) stock in their portfolio include Invesco S&P SmallCap 600 Pure Value ETF (RZV), ETFMG Treatments Testing and Advancements ETF (GERM), Cultivar ETF (CVAR), Invesco S&P SmallCap Health Care ETF (PSCH), First Trust Small Cap Value AlphaDEX Fund (FYT), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What guidance has Emergent BioSolutions issued on next quarter's earnings? Emergent BioSolutions issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.10 billion-$1.20 billion, compared to the consensus revenue estimate of $1.13 billion. What is Bob Kramer's approval rating as Emergent BioSolutions' CEO? 38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees. What other stocks do shareholders of Emergent BioSolutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV). What is Emergent BioSolutions' stock symbol? Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS." Who are Emergent BioSolutions' major shareholders? Emergent BioSolutions' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (18.37%), State Street Corp (10.72%), Dimensional Fund Advisors LP (3.59%), Hotchkis & Wiley Capital Management LLC (1.87%), Geode Capital Management LLC (1.78%) and Charles Schwab Investment Management Inc. (1.63%). Insiders that own company stock include Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View institutional ownership trends. How do I buy shares of Emergent BioSolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Emergent BioSolutions' stock price today? One share of EBS stock can currently be purchased for approximately $8.18. How much money does Emergent BioSolutions make? Emergent BioSolutions (NYSE:EBS) has a market capitalization of $412.68 million and generates $1.12 billion in revenue each year. The biopharmaceutical company earns $-223,800,000.00 in net income (profit) each year or ($8.06) on an earnings per share basis. How many employees does Emergent BioSolutions have? The company employs 2,500 workers across the globe. How can I contact Emergent BioSolutions? Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899. This page (NYSE:EBS) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.